Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million
Mandate

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

March 25, 2026 Capital Markets and Public M&A

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.


The issuances were directed to new U.S. sector specialist investors. One of the issuances of warrants is subject to approval by an extraordinary general meeting.

Vinge’s team consisted of Dain Hård Nevonen, Lorin Arabi, Elias Kröger and Johannes Ekbom (Capital Markets and Public M&A).

Related

Vinge advises Latour on the sale of shares in ASSA ABLOY and Securitas, amounting to SEK 2.5 billion in each company

 Vinge has advised Investmentaktiebolaget Latour (publ) in connection with the sale of parts of its shareholdings in ASSA ABLOY and Securitas for a total value of SEK 5 billion.
May 27, 2026

Vinge advises Hybridge Group on the acquisition of NESC

 Hybridge Group and the consultancy firm NESC are merging. Through the merger, Hybridge Group is strengthening its offering in the field of prefabricated structural solutions.
May 27, 2026

Vinge advises Natur & Kultur in connection with the acquisition of Majema

 Natur & Kultur has acquired 80 per cent of the shares in the educational publisher Majema. The acquisition is a strategic, long-term step in Natur & Kultur’s investment in educational materials.
May 27, 2026